

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		09423698	
	Filing Date		2000-02-10	
	First Named Inventor	Odile Leroy		
	Art Unit	1645		
	Examiner Name	Patricia Ann Duffy		
Attorney Docket Number		99-849-A		

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	03/051392	WO	A2	2003-06-26	GlaxoSmithKline Biologicals S.A.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09423698
Filing Date	2000-02-10
First Named Inventor	Odile Leroy
Art Unit	1645
Examiner Name	Patricia Ann Duffy
Attorney Docket Number	99-849-A

1	Steinoff, M.C. et al. (1994) A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. <i>Pediatr. Infect. Dis. J.</i> Vol. 13 (5), pages 368-372.	<input type="checkbox"/>
2	Chiu, S.S. et al. (1995) Safety and immunogenicity of a pentavalent pneumococcal conjugate vaccine (PPCV) in healthy toddlers. Presented at the 35th Intersc. Conf. Antimicrob. Agents and Chemotherapy, San Francisco Abstr G71, page 171.	<input type="checkbox"/>
3	Daum, R.S. et al. (1995) Immunogenicity of S Pneumoniae oligo- and polysaccharide- CRM197 conjugate vaccines in healthy US infants. Presented at the 35th Intersc Conf. Antimicrob. Agents and Chemotherapy, San Francisco Abstr G65, page 170.	<input type="checkbox"/>
4	O'Brien, K.L. et al. (1996) Immunologic priming of young children by pneumococcal glycoprotein conjugate but not polysaccharide, vaccines <i>Pediatr. Infect. Dis. J.</i> Vol. 15 (5) pages 425-430.	<input type="checkbox"/>
5	Rennels, M.B. et al. (1996) Abstract from Immunogenicity and Safety of 7-Valent Pneumococcal-CRM-197 Conjugate Vaccine. <i>Pediatric Research</i> , Vol. 39 (4) part 2, page 183A. Abstr 1082.	<input type="checkbox"/>
6	Shelly, M.A. et al. (1997) Comparison of pneumococcal polysaccharide and CRM197 conjugated pneumococcal oligosaccharide vaccines in young and elderly adults <i>Infection & Immunity</i> Vol. 65(1) pages 242-247.	<input type="checkbox"/>
7	Kennedy, D. et al. (1994) Immunologic response of 12-18 months old children to licensed pneumococcal polysaccharide vaccine (PS) primed with Streptococcus pneumoniae 19F conjugate vaccine (CV). Presented at the 34th Intersc Conf. Antimicrob. Agents and Chemotherapy Orlando Abstract G88, page 236.	<input type="checkbox"/>
8	Nieminen, T. et al. (1994) Mucosal and serum immune response to tetravalent pneumococcal (SPn) conjugate vaccines (SpnD and SpnT) in adults. Presented at the 34th Intersc. Conf. Antimicrob. Agents and Chemotherapy Abstract G89, page 236.	<input type="checkbox"/>
9	Portier, H. et al. (1994) Serum antibody response to a tetravalent pneumococcal tetanus toxoid conjugate vaccine in adult volunteers. Presented at the 34th Intersc. Conf. Antimicrob. Agents and Chemotherapy Abstract G91, page 236.	<input type="checkbox"/>
10	Keyserling, H. et al. (1994) Immunogenicity of type 14 conjugate vaccine in infants. Presented at the annual meeting of the American Pediatric Society/Society for Pediatric Research Seattle, WA. Abstract 1087, page 184A.	<input type="checkbox"/>
11	Kennedy, D. et al. (1994) Immunologic response to licensed pneumococcal polysaccharide vaccine (PS) in infants primed with heptavalent Streptococcus pneumoniae conjugated vaccine. Presented at the 34th Intersc. Conf. Antimicrob. Agents in Chemotherapy, Orlando Abstract G90, page 236.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09423698
Filing Date	2000-02-10
First Named Inventor	Odile Leroy
Art Unit	1645
Examiner Name	Patricia Ann Duffy
Attorney Docket Number	99-849-A

12	Kayhty, H. et al. (1995) Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J. Infect. Dis Vol. 172, pages 1273-1278.	<input type="checkbox"/>
13	Dagan, Ron et al. (1996) Reduction of Nasopharyngeal Carriage of Pneumococci during the Second Year of Life by a Heptavalent Conjugate Pneumococcal Vaccine. The Journal of Infectious Diseases Vol. 174, pages 1271-1278.	<input type="checkbox"/>
14	SOOD, RAMESH K., ET AL., "Capsular Polysaccharide-Protein Conjugate Vaccines," Research Focus Reviews, DDT, September 1996, pages 381-387, vol. 1, no. 9, Elsevier Science Ltd.	<input type="checkbox"/>
15	SARNAIK, SHARADA MD, ET AL., "Studies on Pneumococcus Vaccine Alone or Mixed With DTP and on Pneumococcus Type 6B and Haemophilus Influenzae Type b Capsular Polysaccharide-Tetanus Toxoid Conjugates in Two Five-Year-Old Children With Sickle Cell Anemia," Pediatric Infect. Dis. J., vol. 9, pp 181-6 (1990).	<input type="checkbox"/>
16	ANDREW, P.W., ET AL., "Pneumococcal Vaccines," Freer et al. (Eds.), Bacterial Protein Toxins, Zbl. Bakt. Suppl. 24, 1994, pages 453-466, Gustave Fischer, Stuttgart, Jena, New York.	<input type="checkbox"/>
17	DAGAN, RON, ET AL., "Reduction of Pneumococcal Nasopharyngeal Carriage in Early Infancy After Immunization with Tetravalent Pneumococcal Vaccines Conjugated to Either Tetanus Toxoid or Diphtheria Toxoid," Pediatr Infect. Dis. J., 1997, pages 1060-1064, vol. 16, no. 11, Williams & Wilkins.	<input type="checkbox"/>
18	LINDBERG, A. A., "Recent Trends in the Developments of Bacterial Vaccines," Brown F. (ed): New Approaches to Stabilisation of Vaccines Potency. Dev Biol. Stand. Basel, Karger, 1996, pages 59-71, vol. 87.	<input type="checkbox"/>
19	GREENBERG, DAVID, P., ET AL., "Factors Influencing the Immunogenicity of a Pneumococcal Conjugate Vaccine in Infants + 709," Pediatric Research: April 1997 - Volume 41 - Issue 4, Part 2 - p 121; 1997 Abstracts The American Pediatric Society and The Society for Pediatric Research.	<input type="checkbox"/>
20	Ahman et al., Abstracts of the 35th ICAAC, 1995, G69, "Immunogenicity of tetravalent pneumococcal (Pnc) conjugate vaccines (PnC, PnCt) in Finnish infants.	<input type="checkbox"/>
21	Schutze et al, 1985, J1, Vol. 135 (4), pp. 2319-2322	<input type="checkbox"/>
22	DE VELASCO, Alonso, et al., "Microbiological Reviews, 1995, pp. 591-603	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09423698
Filing Date	2000-02-10
First Named Inventor	Odile Leroy
Art Unit	1645
Examiner Name	Patricia Ann Duffy
Attorney Docket Number	99-849-A

23	Insel, 1995, Annuals New York Academy of Science, pp. 35-47.	<input type="checkbox"/>
24	GALELLI, et al., 1990, JI, pp. 2397-2405.	<input type="checkbox"/>
25	BARINGTON, et al., 1993, Infection and Immunity, Vol. 61 (2), pp. 432-438	<input type="checkbox"/>
26	DI JOHN, et al., 1989, The Lancet, December 16, pp. 1415-1418.	<input type="checkbox"/>
27	LECLERC, et al., 1990, JI, Vol. 145 (5), pp. 1343-1349.	<input type="checkbox"/>
28	CLEMENS, et al., 1995, Annuals New York Academy of Science, pp.255-266.	<input type="checkbox"/>
29	MOLRINE, et al., 1995, Annals of Internal Medicine, Vol. 123, pp. 828-834.	<input type="checkbox"/>
30	ANDERSON, et al., 2003, Vaccine, Vol. 21, pp.1554-1559	<input type="checkbox"/>
31	PEETERS, et al., 1996, Methods In Molecular Medicine, Vaccine Protocols, pp. 111-133.	<input type="checkbox"/>
32	ANDRE, 1999, Combination vaccines based on DTP, Novel enabling Technologies for Vaccine development, London, 26-27 January 1999.	<input type="checkbox"/>
33	ANDERSON, et al., 1989, J. Immunol., Vol. 142(7), pp. 2464-2468	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09423698
Filing Date	2000-02-10
First Named Inventor	Odile Leroy
Art Unit	1645
Examiner Name	Patricia Ann Duffy
Attorney Docket Number	99-849-A

34	BUTLER, et al., 1994, J. Infect Dis., Vol. 171(4), pp. 885-889.	<input type="checkbox"/>
35	DAGAN, et al., 2004, Pediatr Infect Dis J, Vol. 23, pp. 91-98	<input type="checkbox"/>
36	ELLIS and GRANOFF, 1994, Preface to developmnet and clincial uses of Haemophilus b conjugate vaccines, Marcel Dekker Inc.	<input type="checkbox"/>
37	ESKOLA et al., 1996, Lancet, Vol. 348, pp. 1688-1692.	<input type="checkbox"/>
38	TODAR, Kenneth, Department of Bacteriology, University of Wisconsin, Todar's online textbook of bacteriology, 2002, Immune defense against microbial pathogens.	<input type="checkbox"/>
39	SVENSON and LINDBERG, 1978, J. Immunol. Meth., Vol. 25(4), pp. 323-335.	<input type="checkbox"/>
40	SVENSON and LINDBERG, 1981, Infect. Immun., Vol. 32(2). pp. 490-496.	<input type="checkbox"/>
41	WUORIMAA, et al., 2001, J. Infect. Dis., Vol. 184(9), pp. 1211-1215.	<input type="checkbox"/>
42	WUORIMAA, et al., 2005, Vaccine, Vol. 23, pp. 5328-5332.	<input type="checkbox"/>
43	SCHNEERSON, et al., 1984, Infect. Immun., Vol. 45(3), pp. 582-591.	<input type="checkbox"/>
44	CHO, et al., 1995, 35th ICAAC San Francisco, p. 172, abstract.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09423698
Filing Date	2000-02-10
First Named Inventor	Odile Leroy
Art Unit	1645
Examiner Name	Patricia Ann Duffy
Attorney Docket Number	99-849-A

45	KUO, et al., July 1995, Int. Imm., Vol. 63(7), pp. 2706-2713.	<input type="checkbox"/>
46	EBY, et al., 1994, Vaccine 94, Pneumococcal Conjugates Vaccines, Modern Approaches to New Vaccines Including Prevention of AIDS, Cold Spring Harbor Press, pp. 119-123.	<input type="checkbox"/>
47	LINDBERG AA., 1991, "Polysaccharide vaccines: vaccines needed for the 1990s", In; R. Norrby (ed) Frontiers In Bacteriology, pp. 69-85	<input type="checkbox"/>
48		<input type="checkbox"/>
49		<input type="checkbox"/>
50		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.